Skip to main content
Fig. 79 (abstract P383). | Journal for ImmunoTherapy of Cancer

Fig. 79 (abstract P383).

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Fig. 79 (abstract P383).

TBRI inhibition augments anti-CTLA-4 antibody but not anti-PD-1 antibody immunotherapy in the BRAF(V600E)-PTEN−/− transgenic melanoma model. a Assay 1. Short duration combination TGFBi (TGF-beta inhibitor)-anti-CTLA-4 antibody therapy. b Assay 2. Longer duration TGFBi-anti-CTLA-4 antibody therapy. c Combination TGFBi-anti-PD-1 antibody therapy

Back to article page